^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
Published date:
09/14/2020
Excerpt:
We validated LDH release assay to study induction of ADCC by C and A in 13 human lung cancer cell lines,...Treatment with C plus A induced ADCC in vitro, with higher efficacy in cell lines with high EGFR expression.
